The value of second-look operation in patients with advanced epithelial ovarian carcinoma
- 1 January 1989
- journal article
- research article
- Published by Springer Nature in Archiv für Gynäkologie
- Vol. 244 (2) , 79-86
- https://doi.org/10.1007/bf00931377
Abstract
A second-look operation was performed on 151 patients with stage III and IV epithelial ovarian carcinoma who had responded to primary surgery and chemotherapy. 19% of the 79 patients who appeared clinically to be free of disease had microscopic recurrences and 23% had macroscopic residual disease at a second-look operation. The 5-year survival rate for patients with no histological and for those with microscopic secondaries at second-look operation were 55% and 35% respectively (P=0.45). Only patients with well or moderately well differentiated tumors and a small residual tumor mass at first operation had a good prognosis after a second-look operation even without further chemotherapy. Median survival after secondary debulking was 15 to 17 months and was independent in the radicality of the second-look procedure. Outside of clinical trials second-look laparotomy should therefore only be performed as a diagnostic procedured as a diagnostic procedure in patients with well or moderately well differentiated tumors who are left with a small residual tumor mass at the time of the first operation. Because this is a group of patients in whom chemotherapy can be discontinued after a negative second-look operation.This publication has 15 references indexed in Scilit:
- Radioimmunoscintigraphy Using Monoclonal Antibodies before Second-Look Surgery in Patients Suffering from Ovarian CancerGynecologic and Obstetric Investigation, 1987
- OVARIAN-CANCER RECURRENCES IN PATIENTS WITH NO MACROSCOPIC TUMOR AT 2ND-LOOK LAPAROTOMY1986
- COMPLETE REMISSION AT LAPAROTOMY: STILL A GOLD STANDARD IN OVARIAN CANCER?The Lancet, 1986
- Ergebnisse der ersten multizentrischen österreichischen Ovarialkarzinomstudie: Prospektiv randomisierter Vergleich einer sequentiellen Chemotherapie (Adriamycin/Cisplatin - Vincristin/Cyclophosphamid - Methotrexat) mit 2 Standard-Schemata (Adriamycin/Cyclophosphamid oder Adriamycin/Cisplatin) bei Patientinnen der Stadien III und IVGeburtshilfe und Frauenheilkunde, 1985
- Second-look laparotomy in ovarian cancer: Evaluation of pathologic variablesAmerican Journal of Obstetrics and Gynecology, 1985
- Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1985
- SURVIVAL OF PATIENTS FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY IN OVARIAN-CANCER1983
- Second-look operations in the planned management of advanced ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1982
- Evaluation of survival data and two new rank order statistics arising in its consideration.1966
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958